Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis

Overview

national and multi-center trial for medical therapy of chronic radiation proctitis inducing anorectal bleedings

Full Title of Study: “A Multicenter, Randomized, Double Blind Placebo Controlled Trial of Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: February 26, 2023

Detailed Description

Radiation proctitis is an inflammation of rectal mucosa, a complication following radiation therapy for cancers of the prostate, cervix, uterus, bladder and other malignancies in the pelvic area. Around 20 % of radiation patients develop radiation proctitis. There is a significant lack of trial treatments for radiation proctitis, even more, the studies often are small and single center designed or case series. In 2 recent reviews pointing out the management of radiation proctitis (2018 and 2016) a summary of current options in therapy according to current scientific knowledge is given. Unfortunately, these studies are about interventional options with the serious risk of complication. Only little data and lack of significance in smaller series on conservative strategies are given. The goal of the trial is to implement a specific medication in the management and every grade of radiation proctitis – concomitant to eventual need of MMPF is described with potent anti-inflammatory mucosal capacity reducing bleeding, pain and urgency symptoms in patients with hemorrhoidal and/or postoperative symptoms. By using a placebo instead of comparative oral medications (with low evidence) this study might illustrate clinical significance of expected results as well as information on the natural history of radiation proctitis. The goal of the study is to compare the number of necessary interventions required to stop bleeding in chronic radiation proctitis in patients receiving MMPF in comparison to patients in the control group receiving Placebo within 12 months of medical treatment.

Interventions

  • Drug: MMPF (Micronized purified Flavonoid-Fraction)
    • 500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening
  • Other: Placebo
    • 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily

Arms, Groups and Cohorts

  • Experimental: Investigational
    • Patients receive MMPF 500mg for one year
  • Placebo Comparator: Placebo
    • Patients receive Placebo for one year

Clinical Trial Outcome Measures

Primary Measures

  • Number of necessary intervention
    • Time Frame: Day 1- Day 360
    • Interventions to stop acute bleeding by chronic radiation proctitis: surgical, endoscopic or proctoscopic interventions

Secondary Measures

  • Quality of life of patients
    • Time Frame: Day 0 Day 180 Day 360
    • Differences in quality of life of patients will be measured with evaluation of two questionnaires (EORTC QLQ C30 & PRT20). Higher scores mean a better quality of life.
  • Blood samples
    • Time Frame: Day 0-Day 360
    • Differences in serum hemoglobin, thrombocytes, coagulation parameters (quick/pt=prothrombin time)
  • Stool
    • Time Frame: Day 0-Day 360
    • Differences in calprotectin stool level
  • Presence of histological alterations
    • Time Frame: Day 0-Day 360
    • Differences in histological alterations (distortion of crypts, Inflammation of crypts, fibrosis and ectasia of vessels, cytokines)

Participating in This Clinical Trial

Inclusion Criteria

  • signed informed consent form – male and female patients – age ≥ 18 years – patients with diagnosis of radiation proctitis with macroscopic bleeding – end of radiotherapy ≥ 3 month = 90 days ago Exclusion Criteria:

  • infectious proctitis – ulcerative proctitis (inflammatory bowel disease) – persons unable to understand the informed consent – persons, who are in dependent relationship with the study investigators or Sponsor – pregnant or lactating women – participation in an interventional study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medical University Innsbruck
  • Collaborator
    • Servier Affaires Médicales
  • Provider of Information About this Clinical Study
    • Principal Investigator: Irmgard E Kronberger, MD, Principle Investigator – Medical University Innsbruck
  • Overall Contact(s)
    • Irmgard Kronberger, MD, +43 512 504, irmgard.kronberger@i-med.ac.at

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.